Medication info
Zadium Duo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Zadium Duo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Light brownish purple, oval, biconvex film-coated tablet
Packaging
60 tablets/box (10 tablets/PTP x 6), 10 tablets/box (10 tablets/PTP x 1), 60 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202302747 · Approved 2023.09.13 · Insurance code 694004430

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose when taking this drug is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see item 1) under section 3. Patients Requiring Caution in Administration in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see item 2) under section 2. Patients in Whom the Drug Must Not Be Administered in Precautions for Use). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose control disorder
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to improve blood glucose control in adults with type 2 diabetes, as an adjunct to dietary and exercise therapy. It particularly enhances blood glucose control when empagliflozin and metformin are used in combination. Special caution is advised for patients with cardiovascular diseases whose blood glucose is inadequately controlled, and clinical trial information from specialists should be referenced. This medication effectively improves blood glucose control in type 2 diabetes patients.

How to take

Adult dose

The recommended dose of this drug is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended dose when taking this drug is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this drug from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This drug should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this drug, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this drug contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this drug is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see item 1) under section 3. Patients Requiring Caution in Administration in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately (see item 2) under section 2. Patients in Whom the Drug Must Not Be Administered in Precautions for Use). Elderly Patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for diabetes management and contains two active components. Firstly, metformin hydrochloride lowers blood glucose but may lead to a rare side effect known as severe lactic acidosis, requiring caution. Secondly, empagliflozin increases glucose excretion in the urine, which may elevate the risk of urinary tract infections or genital infections. This medication should not be used in patients with severely impaired kidney function, acute infections, heart failure, or other serious conditions. It is also not recommended for pregnant or nursing women or patients with impaired liver function. During treatment, kidney function should be regularly monitored, especially in elderly patients or those with mildly impaired kidney function, who require closer observation. Caution must be taken to avoid fluid loss due to dehydration, severe vomiting, or diarrhea during treatment; if such symptoms occur, discontinue the medication and consult a physician. If taken alongside other diabetes medications such as insulin or sulfonylureas, there may be an increased risk of hypoglycemia, necessitating dosage adjustments. Serious metabolic disturbances such as lactic acidosis and ketoacidosis may occur. If symptoms like malaise, muscle pain, shortness of breath, or abdominal pain arise, inform healthcare personnel immediately. It is advisable to avoid alcohol consumption during treatment for blood glucose control, and to temporarily suspend use before surgeries or tests involving iodine contrast agents. Increased urination or symptoms of urinary tract infections or genital infections may occur during treatment; notify healthcare personnel if these symptoms appear. The safety of this medication in pediatric patients has not been established and is not recommended for those under 18. Furthermore, elderly patients require careful management due to the risks of kidney function decline and fluid loss. In cases of overdose, there is a risk of hypoglycemia or lactic acidosis, requiring immediate hospital treatment, and possible blood dialysis. This medication should be stored out of reach of children and kept in its original container for safety.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • decreased fluid volume
  • nausea
  • vomiting
Show 146 more
  • diarrhea
  • abdominal pain
  • anorexia
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • perineal gangrene
  • vulvar moniliasis
  • vulvitis
  • balanitis
  • fluid volume loss
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorder
  • headache
  • cerebral infarction
  • sensory impairment
  • orthostatic dizziness
  • dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent narrowing
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urinary stones
  • acute kidney injury
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • taut retinal detachment
  • eyelid swelling
  • visual impairment
  • floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • bruise
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliolumbar ligament syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a sealed container to avoid exposure to air or moisture, and the storage temperature should be maintained between 1 to 30 degrees Celsius (room temperature). This is essential to preserve the medication's effectiveness and ensure its safe use.

Appearance and packaging

Appearance

Light brownish purple, oval, biconvex film-coated tablet

Package unit

60 tablets/box (10 tablets/PTP x 6), 10 tablets/box (10 tablets/PTP x 1), 60 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.